These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

981 related articles for article (PubMed ID: 17116941)

  • 21. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
    Toi M; Nakamura S; Kuroi K; Iwata H; Ohno S; Masuda N; Kusama M; Yamazaki K; Hisamatsu K; Sato Y; Kashiwaba M; Kaise H; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Takatsuka Y;
    Breast Cancer Res Treat; 2008 Aug; 110(3):531-9. PubMed ID: 17879158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant docetaxel for node-positive breast cancer.
    Martin M; Pienkowski T; Mackey J; Pawlicki M; Guastalla JP; Weaver C; Tomiak E; Al-Tweigeri T; Chap L; Juhos E; Guevin R; Howell A; Fornander T; Hainsworth J; Coleman R; Vinholes J; Modiano M; Pinter T; Tang SC; Colwell B; Prady C; Provencher L; Walde D; Rodriguez-Lescure A; Hugh J; Loret C; Rupin M; Blitz S; Jacobs P; Murawsky M; Riva A; Vogel C;
    N Engl J Med; 2005 Jun; 352(22):2302-13. PubMed ID: 15930421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
    Nakamura S; Ando M; Masuda N; Aogi K; Ino H; Iwata H; Tokuda Y; Yamamoto N; Kasai H; Takeuchi M; Tsuda H; Akiyama F; Kurosumi M; Fujiwara Y
    Clin Breast Cancer; 2012 Feb; 12(1):49-56. PubMed ID: 22154118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
    Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
    Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
    Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
    J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
    Wildiers H; Dirix L; Neven P; Prové A; Clement P; Squifflet P; Amant F; Skacel T; Paridaens R
    Breast Cancer Res Treat; 2009 Mar; 114(1):103-12. PubMed ID: 18344024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
    Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
    Delbaldo C; Serin D; Mousseau M; Greget S; Audhuy B; Priou F; Berdah JF; Teissier E; Laplaige P; Zelek L; Quinaux E; Buyse M; Piedbois P;
    Eur J Cancer; 2014 Jan; 50(1):23-30. PubMed ID: 24183460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
    Moebus V; Jackisch C; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Schneeweiss A; Huober J; Harbeck N; von Minckwitz G; Runnebaum IB; Hinke A; Kreienberg R; Konecny GE; Untch M
    J Clin Oncol; 2010 Jun; 28(17):2874-80. PubMed ID: 20458045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
    J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
    Kelly CM; Green MC; Broglio K; Thomas ES; Brewster AM; Valero V; Ibrahim NK; Gonzalez-Angulo AM; Booser DJ; Walters RS; Hunt KK; Hortobagyi GN; Buzdar AU
    J Clin Oncol; 2012 Mar; 30(9):930-5. PubMed ID: 22331946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
    Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
    Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
    J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
    J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.
    Younis T; Rayson D; Sellon M; Skedgel C
    Breast Cancer Res Treat; 2008 Sep; 111(2):261-7. PubMed ID: 17914669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.